Toremifene in Treating Patients With Ovarian Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed serous papillary carcinoma of the ovary
• * Recurrent or refractory disease following at least one regimen including paclitaxel, cisplatin, or carboplatin
• Measurable disease outside of irradiated field
• No CNS metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Zubrod 0-2
• Life expectancy:
• At least 16 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,800/mm\^3
• Platelet count at least 125,000/mm\^3
• No history of thrombosis or thromboembolic events
• Hepatic:
• Bilirubin no greater than 2.0 mg/dL
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study
• No other concurrent second malignancy or prior malignancy within past 5 years, except basal or squamous cell skin cancer or curatively treated stage I carcinoma of the cervix
• No concurrent infection
• At least 3 days since prior fever (unless due to tumor)
• No other concurrent severe medical illness
• No HIV positivity
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• No concurrent chemotherapy
• Endocrine therapy:
• No prior tamoxifen or antiestrogen therapy
• Radiotherapy:
• See Disease Characteristics
• At least 6 months since prior radiotherapy
• No concurrent radiotherapy except to symptomatic or potentially disabling bone lesion accompanied by other measurable disease
• Surgery:
• Not specified
• Other:
• No concurrent anticoagulants
• No other concurrent therapeutic trials